LEON sets up lab facilities at the Innovation and Start-Up Center for Biotechnology (IZB) in Munich

LEON sets up lab facilities at the Innovation and Start-Up Center for Biotechnology (IZB) in Munich

• LEON has taken residence at the Munich Biotech Hub IZB
• Dedicated in-house lab facilities support late-stage product development
• New capacities to serve as base for future process development services for clients

April 27, 2023 – Munich (Germany) – leon-nanodrugs GmbH (“LEON”), a disrupting enabler of nanotechnology for the pharmaceutical industry, today announced the establishment of their own lab facilities at the Start-Up Center for Biotechnology (IZB) in Munich. The new R&D capacities set the stage for completion of product development for LEON’s manufacturing devices and will afterwards be used to showcase the devices and provide process development services to clients using LEON's equipment.

LEON's product platform is built on their proprietary innovative FR-JET Technology that enables a huge efficiency increase in the formulation process of active ingredients into nanodrug carriers such as lipid nanoparticles (LNPs).  LEON's devices, NANOme and NANOus, are designed for aseptic processing, GMP-compliance and quick scale-up. NANOme is optimized for small-scale individual patient and clinical trial-size production. NANOus is a fully-automated, aseptic device enabling the LNP-encapsulation of APIs from medium- to large-scale with high throughput using process analytical technology (PAT).

Dr. Setu Kasera, Head of Science and Engineering, commented: “We are truly excited about moving into the IZB. As one of the key biotech hubs in Germany, the IZB provides not only lab facilities, but also an unparalleled environment to foster innovation and growth. The local proximity to biotech start-ups, academia, VCs and big pharma creates an ecosystem that facilitates networking in- and outside of your peer group, setting the stage for future cooperations and partnerships. We are looking forward to using our new capacities to complete the development of our devices for the market, while we pursue and build on opportunities for collaborations by providing access to our devices and process development services.”

“We welcome LEON to our vibrant biotech center. At IZB, we strive to support companies that bring new technologies and approaches to the biotech industry, and I am confident the resources and network available at the campus will support LEON in their late-stage product development,” added Dr. Peter Hanns Zobel, Managing Director IZB.
 

ABOUT LEON-NANODRUGS

leon-nanodrugs GmbH (“LEON”) is a pharmatech company specializing in the development and marketing of devices for the encapsulation of genetic material and other active substances into nanodrug carriers, such as lipid nanoparticles (LNPs). The Munich-based private company builds its innovative solutions on its proprietary FR-JET technology, enabling pharma companies, small biotech as well as CDMOs to optimize nanomedicine manufacturing and take full advantage of the significant progress being made in advanced therapies.

LEON's GMP-compliant, aseptic devices NANOme and NANOus increase efficiency in the production of nano drug carriers and are suitable for both clinical scale and commercial production. In addition to its product offering LEON will provide in-house lab capacity for process development with its own devices.

For further information, please visit https://leon-nanodrugs.com/ and follow us on LinkedIn and Twitter.